HER2-Positive Breast Carcinoma clinical trials
6 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
- Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- TRUDI: TDXD+Durva in HER2+/Low IBC
- Study of Screening Brain MRIs in Stage IV Breast Cancer
- Role of the Immune Environment in Response to Therapy in Breast Cancer
- Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
- Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “HER2-Positive Breast Carcinoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.